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Abstract
Transforming growth factor-beta-induced protein (TGFBIp) is ubiquitously expressed in the
extracellular matrix (ECM) of various tissues and cell lines. Progressive accumulation of
mutant TGFBIp is directly involved in the pathogenesis of TGFBI-linked corneal dystrophy.
Recent studies reported that mutant TGFBIp accumulates in cells; however, the trafficking
of TGFBIp is poorly understood. Therefore, we investigated TGFBIp trafficking to determine
the route of its internalization and secretion and to elucidate its roles in the pathogenesis of
granular corneal dystrophy type 2 (GCD2). Our data indicate that newly synthesized
TGFBIp was secreted via the endoplasmic reticulum/Golgi-dependent secretory pathway,
and this secretion was delayed in the corneal fibroblasts of patients with GCD2. We also
found that TGFBIp was internalized by caveolae-mediated endocytosis, and the internal-
ized TGFBIp accumulated after treatment with bafilomycin A1, an inhibitor of lysosomal
degradation. In addition, the proteasome inhibitor MG132 inhibits the endocytosis of
TGFBIp. Co-immunoprecipitation revealed that TGFBIp interacted with integrin αVβ3. More-
over, treatment with arginine-glycine-aspartic acid (RGD) tripeptide suppressed the inter-
nalization of TGFBIp. These insights on TGFBIp trafficking could lead to the identification of
novel targets and the development of new therapies for TGFBI-linked corneal dystrophy.
Introduction
TGFBI-linked corneal dystrophies are autosomal dominant disorders caused by mutations in
transforming growth factor-beta-induced (TGFBI) gene [1–3]. These disorders are character-
ized by age-dependent progressive accumulation of deposits of mutant TGFBIp in the corneal
epithelia and stroma, followed by interference with corneal transparency [1]. Granular corneal
dystrophy type 2 (GCD2) is an autosomal dominant disorder caused by a mutation in codon
124 of the TGFBI gene that results in an arginine-to-histidine substitution (R124H) [1].
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TGFBIp is expressed in various tissues such as cornea, skin, lung, bone, bladder, and kidney
[4,5]. TGFBIp is an extracellular matrix (ECM) protein with a secretory signal sequence and
cysteine-rich (EMI) domain at the N-terminus, four homologous internal fasciclin (FAS1) do-
mains, and an Arg-Gly-Asp (RGD) integrin recognition sequence at the C-terminus [6]. In
vitro studies have shown that TGFBIp mediates cell growth [7], cell differentiation [8], wound
healing [9], cell adhesion [10], migration [11], apoptosis [12], proliferation [11], and tumori-
genesis [13]. Moreover, TGFBIp mediates migration and cell adhesion through its interaction
with cell surface integrin receptors [14–16].
Most secretory proteins contain signal peptides that lead to direct sorting to the endoplas-
mic reticulum (ER). These proteins are typically trafficked to the plasma membrane or ECM
through the ER/Golgi secretory pathway [17], although some proteins are trafficked via an un-
conventional non-ER/Golgi secretory pathway. After ER translocation, proteins are packaged
into coated vesicles that either fuse directly with the plasma membrane or with endosomal or
lysosomal compartments before adhering to the plasma membrane. Alternatively, proteins can
be packaged into non-coated vesicles that fuse directly with the plasma membrane or are tar-
geted to the Golgi apparatus before reaching the ECM [18]. In addition to its recognition as a
cellular degradation pathway that delivers cytoplasmic proteins and organelles to lysosomes
for subsequent degradation, autophagy has also been demonstrated to play a role in unconven-
tional protein secretion [19].
Endocytosis is a basic cellular process in eukaryotic cells that leads to the internalization of
molecules from the cell surface. Internalized molecules from the plasma membrane are recy-
cled back to the surface or sorted to lysosomes for degradation. Endocytosis could be classified
into two broad categories: phagocytosis (the internalization of large particles) and pinocytosis
(the internalization of fluids and solutes) [20]. The major endocytic pathways are usually dis-
tinguished by their differential sensitivity to inhibitors [21]; for example, caveolae- and lipid
raft-mediated endocytosis from the clathrin-dependent pathway can be identified by sensitivity
to non-acute cholesterol depletion with agents such as filipin, genistein, nystatin, or methyl-
β-cyclodextrin.
Degradation and removal of ECM proteins is associated with several physiological process-
es, including tissue development, remodeling, and repair [5,22]. ECM remodeling is controlled
by matrix synthesis, deposition, and degradation. Two molecular mechanisms are believed to
be involved in ECM turnover. The first pertains to extracellular degradation of ECM proteins
by matrix metalloproteases and other proteases [23,24], and the second involves lysosomal
degradation of internalized ECM proteins following endocytosis [22,25,26]. Impaired ECM ho-
meostasis contributes to the progression of many diseases, including fibrosis, arthritis, and can-
cer [27–31].
Recently, we demonstrated that mutation in TGFBI causes aberrant redistribution of
TGFBIp into lysosomes [32]. Mutant TGFBIp also accumulated in lysosomal compartments as
a result of defective autophagy [33]. In this study, we sought to gain a better understanding of
the molecular events involved in the trafficking and turnover of ECM proteins containing
TGFBIp. Specifically, we investigated the intracellular and extracellular trafficking of TGFBIp
and its involvement in the pathogenesis of TGFBI-linked corneal dystrophy. Our data demon-
strate that TGFBIp secretion occurs via the ER/Golgi-dependent secretory pathway. However,
this process is delayed in GCD2 corneal fibroblasts. Furthermore, we discovered that TGFBIp
is internalized via a caveolin-dependent integrin-mediated endocytic pathway and is trafficked
directly to the lysosomes. The findings of this study will enable the identification of therapeutic
targets for the treatment of TGFBI-linked corneal dystrophy.
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Materials and Methods
Materials
Chlorpromazine, nystatin, genistein, MG132, bafilomycin A1 (Baf-A1), monensin (MON), bre-
feldin A (BFA), cycloheximide (CHX), Arg-Gly-Asp (RGD)-containing peptide (Gly-Arg-Gly-
Asp-Ser-Pro [GRGDSP]), and RAD control peptide (Gly-Arg-Ala-Asp-Ser-Pro [GRADSP])
were obtained from Sigma-Aldrich (St Louis, MO, USA). hTERT-inducible lentiviral particles
were obtained from GenTarget, Inc. (San Diego, CA, USA). The cell lines HEK293T (ATCC
CRL-3216), NIH3T3 (ATCC CRL-1658), SK-N-MC SK-N-SH (ATCC HTB-11), and 3T3
MEF KO (ATCC CRL-2753) was purchased from the American Type Culture Collection
(ATCC) (Rockville, MD).
Ethics statement
This study was carried out according to the tenets of the Declaration of Helsinki and it followed
international ethic requirements for human tissues. The Severance Hospital Institutional Re-
view Board (IRB: 4-2010-0013) at Yonsei University approved use of corneal biopsy specimens
of patients and controls for study of pathological mechanisms of GCD2 and has previously
been described [34]. All participants provided written informed consent to participate in this
study. The study protocol was approved by the Severance Hospital IRB (CR04124) at Yonsei
University. Written informed consent from participating donors and informed assent from
were all participants obtained according to institution’s IRB policies.
Cell culture
All the cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Corning Cellgro,
Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA,
USA), 100 IU/ml penicillin (Corning Cellgro), 100 μg/mL streptomycin (Corning Cellgro), and
phosphate-buffered saline (PBS; Corning Cellgro). The cells were maintained in a 5% CO2 in-
cubator at 37°C.
Pulse-chase metabolic labeling and immunoprecipitation
Normal and GCD2 corneal fibroblasts were plated onto 35-mm culture dishes and cultured for
24 h. Cells were pre-incubated with cysteine-free DMEM (Sigma-Aldrich) containing dialyzed
0.5% fetal bovine serum (Invitrogen). Cells were incubated (pulsed) with 0.3 mCi/mL [35S] cys-
teine (PerkinElmer Life and Analytical Sciences, Boston, MA, USA) in the same medium for
20 min. After labeling, the cells were washed three times with PBS and incubated (chased) with
DMEM containing 10% FBS at 37°C for 0, 15, 30, 60, 120, 180, or 240 min. The medium was
collected and centrifuged at 4,500 × g for 10 min at 4°C. The cells were harvested in PBS, lysed
in 500 μL RIPA buffer containing protease inhibitors, and centrifuged at 10,000 × g for 10 min
at 4°C. Cell lysates and media were each divided into two equal volumes and immunoprecipi-
tated with anti-TGFBIp and Dynabeads coated with sheep anti-mouse IgG (Invitrogen Dynal).
The immunoprecipitated proteins were separated by 10% Tris/Glycine SDS-PAGE. The gels
were enhanced with ENHANCE (Amersham Pharmacia Biotech) and exposed to Kodak Bio-
Max X-ray films (Kodak, Rochester, NY, USA) for 7 days at −80°C.
Internalization assay and endocytic inhibitors
TGFBIp internalization assays were performed at 37°C and 4°C with or without the following
endocytic inhibitors: 10–100 μg/mL chlorpromazine, 100 μg/mL genistein, and 25 μg/mL nys-
tatin. The involvement of integrins in TGFBIp internalization was examined by incubating
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corneal fibroblasts with an integrin peptide inhibitor (1–10 μMRGD peptides) in the presence
of ~1 μg/mL TGFBIp. Corneal fibroblasts were incubated for 60 min in a medium containing
CHX to block endogenous TGFBIp synthesis and/or with the inhibitors of endocytosis. The
specificity of each treatment was confirmed by incubating the cells with exogenous TGFBIp at
4°C, to allow binding, before incubation at 37°C for 120 min, to allow endocytosis. After incu-
bation, the medium was removed and the cells were washed three times with cold PBS. Endo-
cytosis of TGFBIp was analyzed by western blotting and immunofluorescence staining.
Isolation, immortalization, and culture of primary corneal fibroblasts
Normal and GCD homozygous primary corneal fibroblasts were prepared using previously de-
scribed methods [34]. GCD2 was diagnosed by DNA sequence analysis for TGFBI gene muta-
tions. The normal human corneal fibroblast cell line [35] was kindly provided by Dr. James
Jester. GCD2 corneal fibroblasts were immortalized by expression of the catalytic subunit of
human telomerase (hTERT) using a reversible retroviral expression vector [36]. The primary
corneal fibroblasts (Table 1) were cultured in DMEM supplemented with 10% fetal bovine
serum at 37°C in a humidified incubator with 95% air and 5% CO2. All the cell lines were cul-
tured in DMEM with 10% fetal bovine serum at 37°C in a humidified incubator with 95% air
and 5% CO2.
Preparation of cell lysates, co-immunoprecipitation, and western blot
analysis
Cell lysates from corneal fibroblasts were prepared in a radio-immunoprecipitation assay buff-
er (RIPA buffer; 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl,
pH 7.4) containing protease inhibitors (Complete Mini Protease Inhibitor Cocktail Tablet,
Roche Applied Science, Indianapolis, IN, USA) and phosphatase inhibitors (PhosSTOP, Roche
Applied Science). Crude cell lysates were centrifuged at 10,000 × g for 10 min at 4°C to remove
nuclear fragments and tissue debris. A portion of the supernatant was used to determine the
total protein concentration with a bicinchoninic acid kit (Pierce). Total cellular protein was
electrophoresed on Tris-glycine SDS polyacrylamide gels. Proteins were transferred onto poly-
vinylidene difluoride (PVDF) membranes (Millipore Corp., Bedford, MA, USA), blocked in
Table 1. Cases used for analysis in this Study.
Case No. Pathological diagnosis Gender Age Mean age
1 CON-WT F 20
2 CON-WT M 10 26.25
3 CON-WT M 29
4 CON-WT M 46
5 GCD2-HE F 37
6 GCD2-HE F 20 27
7 GCD2-HE M 24
8 GCD2-HO F 27
9 GCD2-HO M 10
10 GCD2-HO F 13 18
11 GCD2-HO M 22
CON-WT, control case; GCD2-HE, heterozygote of granular corneal dystrophy type 2 case; GCD2-HO, homozygote of granular corneal dystrophy type 2
case; F, female; M, male.
doi:10.1371/journal.pone.0119561.t001
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5% dry milk in Tris-buffered saline containing Tween-20 (TBS-T; 20 mM Tris, 150 mM NaCl,
pH 7.5 containing 0.1% Tween 20) at room temperature for 1 h, washed three times with
TBS-T, and then incubated with primary antibodies to TGFBIp (0.2 μg/mL; R&D Systems,
Minneapolis, MN, USA), caveolin-1 (BD Biosciences, San Jose, CA, USA), caveolin-2 (BD Bio-
sciences), and β-actin (Sigma-Aldrich) overnight at 4°C. After three washes with TBS-T, the
blots were incubated at room temperature for 1 h with horseradish peroxidase-conjugated
anti-mouse IgG or anti-rabbit IgG secondary antibody (Amersham Pharmacia Biotechnology,
Piscataway, NJ). Western blots were visualized using the Super Signal West Pico Chemilumi-
nescent Substrate (Pierce). Immunoreactive protein bands were scanned at two intensities, and
the optical densities of the bands were quantified using the ImageJ software (version 1.37,
Wayne Rasband, NIH, Bethesda, MD), corrected by background subtraction, and normalized
to the intensity of the corresponding β-actin protein bands.
Co-immunoprecipitation was performed with magnetic beads coated with polyclonal anti-
integrin αVβ3 (Chemicon, Temecula, CA, USA) and αV antibody (Chemicon), according to the
manufacturer’s instructions (Invitrogen Dynal, Carlsbad, CA, USA). Immunoprecipitated pro-
teins were separated by SDS-PAGE (8−16% gradient Tris-glycine gel; Komabiotech, Seoul,
Korea) and immunoblotted with TGFBIp antibody (0.2 μg/mL; R&D Systems).
Immunocytochemical staining
WT and GCD2 homozygous mutant (HO) corneal fibroblasts were grown on culture slides
(Cat. No. REF 354108; BD Falcon, Labware, Franklin Lakes, NJ, USA), permeabilized, and
fixed in methanol at −20°C for 3 min. Cells were washed in PBS, blocked with 10% bovine
serum albumin (Sigma-Aldrich) in PBS for 10 min, and incubated sequentially with primary
antibodies in blocking buffer at 4°C overnight, followed by secondary antibodies for 1 h at
room temperature. Coverslips were mounted on glass slides with Vectashield Mounting Medi-
um (Vector Labs Inc., Burlingame, CA, USA) and viewed under a Leica TCS SP5 confocal mi-
croscope (Leica Microsystems, Wetzlar, Germany). The following primary antibodies were
used: monoclonal anti-TGFBIp (kindly provided by Dr. I S Kim, Kyungpook National Univer-
sity, Korea), polyclonal anti-trans-Golgi network (TGN) 38 (Santa Cruz Biotechnology, Santa
Cruz, CA), anti-GM130 (Cell Signaling Technology, Beverly, MA), anti-mannosidase II
(Abcam, Cambridge, UK), and anti-Cathepsin D rabbit polyclonal antibody (Calbiochem, La
Jolla, CA, USA). Alexa 594-conjugated cholera toxin B subunit (CTxB) was obtained from Mo-
lecular Probes, Inc. (Eugene, Oregon, USA). The following secondary antibodies were used:
Alexa 594 (red)-conjugated anti-rabbit IgG (Vector Laboratories Inc., DI-1488) and fluorescein
isothiocyanate (green)-labeled anti-mouse IgG (Jackson ImmunoResearch Laboratories, West
Grove, PA).
Transmission electron microscopy
Cultured corneal fibroblasts were fixed overnight, dehydrated, and processed for electron mi-
croscopy analysis as described previously [37]. Evaluation was performed using a transmission
electron microscope (JEM1200 EX2; JEOL Ltd.). For immunogold-labelling experiments, the
primary antibody (monoclonal anti-TGFBIp antibody) was detected via the standard protein
A–gold method [38].
Statistical analysis
Data were evaluated statistically to determine significant differences (P< 0.05) using one-way
analysis of variance (ANOVA), followed by the Newman−Keuls multiple comparison test.
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Data are expressed as mean ± SD. All the data were processed using the scientific graphing
analysis software (Prism, version 5.0; GraphPad Software Inc., San Diego, CA, USA).
Results
Secretion of TGFBIp via an ER/Golgi-dependent pathway is delayed in
GCD2 corneal fibroblasts
Although studies have established that TGFBIp protein is secreted into the ECM and degraded
via autophagy/lysosomal pathway, the underlying trafficking pathway(s) remain poorly under-
stood. To address this issue, we examined the secretion of TGFBIp in the presence of brefaldin-
A (BFA), which reversibly blocks protein transport from the ER [39] and monensin (MON),
which effectively inhibits protein transport from medial to trans Golgi cisternae [40,41]. In
normal culture conditions, western blot analysis of TGFBIp in cell lysates and conditioned
media of wild-type (WT) and GCD2 homozygous (HO) primary fibroblasts indicated two
forms of the protein at ~66 and ~68 kDa (Fig 1A). The effects of inhibitors on TGFBIp secre-
tion were assessed by incubating cells for 6 h at 37°C in a media containing 5 μg/mL BFA or
5 μMMON. Cells were lysed and western blot analysis of TGFBIp in cell lysates was per-
formed. As shown in Fig 1, TGFBIp secretion was nearly completely abrogated by exposure to
BFA and MON (Fig 1B) in both WT and GCD2 HO corneal fibroblasts. These data demon-
strate that TGFBIp is transported from the ER lumen to the Golgi apparatus and then to the
ECM via the ER/Golgi-dependent secretory pathway; also termed the classical or conventional
secretory pathways. In addition, our data demonstrate that TGFBIp co-localized with the Golgi
proteins GM130 (a cis-Golgi matrix protein), mannosidase II (a medial-Golgi enzyme), and
TGN38 (trans-Golgi network protein 38), suggesting the secretion of newly synthesized
TGFBIp into the ECM via the ER/Golgi-dependent secretory pathway (Fig 1C).
Studies have demonstrated intracellular accumulation of mutant TGFBIp in GCD2 corneal
fibroblasts [33], suggesting the inhibition of TGFBIp secretion. To investigate this possibility,
we performed a pulse-chase experiment in combination with immunoprecipitation to dynami-
cally monitor the secretion of newly synthesized TGFBIp in WT and GCD2 HO corneal fibro-
blasts. Corneal fibroblasts were pulse-labeled with 35S-cysteine for 20 min and then chased for
different time periods. Protein extracts were harvested and subjected to immunoprecipitation
with an anti-TGFBIp monoclonal antibody, followed by 10% SDS-PAGE and autoradiography.
The amounts of secreted and intracellular TGFBIp were quantitated by densitometry. Our re-
sults clearly showed that WT and mutant TGFBIp exhibited different trafficking kinetics (Fig
1D and 1E). At 60 min, nearly all of the newly synthesized WT TGFBIp was secreted into the
culture media, with only 0.5% (standard deviation [SD] ± 0.9%) remaining inside the cells,
whereas 20% (± 0.6%) of mutant TGFBIp was retained inside the cells (Fig 1D and 1E). Most
of the mutant TGFBIp was not secreted into the culture media until 180 min after the chase
(when only 7 ± 4.6% remained inside the cells). Moreover, in normal corneal fibroblasts, the
cellular TGFBIp level decreased to approximately 50% at 20 min (± 2 min) post chase, whereas
a similar reduction in GCD2 homozygous corneal fibroblasts expressing mutant TGFBIp was
observed after 45 min (± 4 min) post chase.
TGFBIp was internalized by endocytosis
In spite of its extensive distribution throughout the ECM, lysosomal degradation of TGFBIp
suggests the possibility of TGFBIp internalization through endocytosis. Therefore, we investi-
gated the endocytosis of TGFBIp in four cell lines: HEK293T, NIH3T3, ZW13-1 [42], and
SK-N-MC. The cells were incubated with exogenous TGFBIp for 2 h at 37°C to allow
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internalization. Quantification of the results showed that HEK293T cells, which do not express
TGFBIp, did not internalize the protein. However, NIH3T3 and ZW13-1 cells, which also do
not express TGFBIp, clearly demonstrated TGFBIp internalization. Furthermore, we detected a
higher level of internalized TGFBIp in SK-N-MC cells, which endogenously express TGFBIp
(Fig 2A).
Fig 1. Expression and secretion of TGFBIp in wild-type (WT) and heterozygous (HE) or homozygous
(HO) mutant primary corneal fibroblasts. A. Western blot analysis of TGFBIp in cell lysates (upper panel)
and conditioned media (lower panel) of WT, HE, and HO cells. β-actin was used as a loading control.
Molecular weight markers (in kDa) are indicated.B. Secretion of WT and mutant TGFBIp was inhibited by
treatment with brefeldin A (BFA) and monensin (MON). C. TGFBIp co-localized with markers of cis-Golgi
(upper panel), medial-Golgi (middle panel), and trans-Golgi (lower panel) in cortical cells. Representative
confocal images of immunofluorescence staining of TGFBIp (green) with GM130, mannosidase II, and
TGN38 (all red) are shown. Overlapping areas are displayed in yellow in the merged images. Bars = 25 μm.
D. Secretion of mutant TGFBIp is delayed in GCD2 corneal fibroblasts. Corneal fibroblasts from a patient with
a homozygous TGFBIp mutation and aWT control were pulse-labeled for 20 min using 35S-cysteine and then
incubated for 0, 15, 30, 60, 120, 180, and 240 min in unlabeled media before immunoprecipitation of TGFBIp
from cell lysates and conditioned media. Phosphorimaging was performed after SDS-PAGE to detect
TGFBIp. One representative experiment is shown. E. Quantitation of the experiment presented in D.
Triplicate lysate samples were analyzed. *P< 0.05.
doi:10.1371/journal.pone.0119561.g001
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We also analyzed time-dependent TGFBIp internalization by western blot (Fig 2B and 2C)
and immunocytochemical staining (Fig 2D). The results showed that TGFBIp internalization
into the cells started immediately after warming, and proceeded rapidly until reaching a maxi-
mum (89% ± 17% and 98% ± 20% in WT- and Mut-TGFBIp, respectively) within 90 min (Fig
2C). After warming, the uptake ratio of TGFBIp internalization reached 29% ± 12% and 54% ±
20% in WT-TGFBIp, and 32% ± 14% and 61% ± 10% in Mut-TGFBIp at 30 min and 60 min,
Fig 2. Internalization of TGFBIp in various cell lines. A. TGFBIp was internalized in NIH3T3, SK-N-MC,
and ZW13-1 cell lines but not in HEK293T. Cells were pre-incubated at 4°C for 30 min in basal medium, and
then incubated for a further 120 min at 37°C in basal or TGFBIp-supplemented (~1 μg/mL) medium. Cells
were washed twice with cold PBS on ice, and surface-bound TGFBIp was removed by washing three times
with ice-cold acidic buffer. Cells were harvested by scraping into ice-cold PBS, pelleted by centrifugation at
1,000 × g, lysed in RIPA buffer, and 50 μg of lysate was used for western blot analysis.B. Internalization of
mutant TGFBIp andWT TGFBIp was similar in NIH3T3 cells. Cells were treated as in A and analyzed by
western blotting.C. Internalization of WT- and Mut-TGFBIp in the NIH3T3 cell line. Cells were incubated at
4°C for 30 min and were then shifted to 37°C in the continuous presence of TGFBIp. At the indicated time
points, cells were analyzed for the amount of internalized TGFBIp. The experiment was repeated three times
independently. There were no statistically significant differences between the rates of WT- and Mut-TGFBIp
internalization (p> 0.05). D. Visualization of TGFBIp internalization in NIH3T3 cells by confocal microscopy.
Cells were grown on glass coverslips and treated as inA, before fixation in methanol at −20°C for 3 min.
Immunocytochemical staining was performed with monoclonal anti-TGFBI antibody, as described in
Materials and Methods. E. TGFBIp co-localizes with Lamp-2. NIH3T3 cells grown on glass slides were
subjected to immunocytochemical staining with monoclonal anti-TGFBIp and anti-Lamp-2 antibodies as
described in Materials and Methods. Coverslips were mounted on the glass slides with mounting medium,
and the cells were viewed using a Leica TCS SP5 confocal microscope.
doi:10.1371/journal.pone.0119561.g002
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respectively. However, the difference in the uptake ratio was not significant between WT- and
mut-TGFBIp (Fig 2C).
Confocal microscopy revealed TGFBIp internalization after incubation for only 10 min
(short incubation period) (Fig 2D). Longer incubation times (60–90 min) led to localization of
TGFBIp in the central part of the cells. Finally, staining for Lamp-2, a marker of late endo-
somes/lysosomes, revealed co-localization with TGFBIp, suggesting that TGFBIp was traf-
ficked to lysosomes in the NIH3T3 cell line (Fig 2E).
Internalization of TGFBIp occurs via caveolae-mediated endocytosis
Next, we investigated whether TGFBIp internalization occurred via clathrin- or caveolae-medi-
ated endocytosis. We treated a corneal fibroblast cell line with the general protein tyrosine ki-
nase inhibitor genistein, which prevents caveolae-mediated internalization [43–46]. Our
results showed that treatment with genistein (100 μg/mL) significantly reduced the amount of
intracellular TGFBIp (Fig 3A and 3B, lane 3). To further confirm the route of TGFBIp internal-
ization, we treated the cells with cholesterol-chelating drug nystatin, which interferes with
caveolae-mediated endocytosis [47–49], and found that nystatin (25 μg/mL) caused a signifi-
cant reduction in intracellular TGFBIp levels (Fig 3A and 3B, lane 4). In contrast, an inhibitor
of clathrin-mediated endocytosis, chlorpromazine (10 or 100 μg/mL), increased the level of in-
tracellular TGFBIp (Fig 3A and 3B, lanes 5), even at higher concentrations (Fig 3A and 3B,
lanes 6). To further confirm whether TGFBIp is internalized via a caveolea-mediated endocyto-
sis, we used caveolin-1-null cell line (3T3 MEF CAV-1 KO). RT-PCR and western blotting
showed that 3T3 MEFs CAV-1 KO cells, which do not express TGFBI gene (S1 Table and S1
Fig), did not internalize TGFBIp (Fig 3C). These results clearly demonstrated that TGFBIp is
internalized by caveolea-dependent endocytosis.
We also demonstrated the co-localization of TGFBIp and caveolin-1 in primary cultured
corneal fibroblasts (Fig 3D). Caveolin-1 staining was localized to the plasma membrane and
other intracellular compartments. Co-localization of caveolin-1 with cathepsin D was also ob-
served, and it increased in the presence of Baf-A1, an inhibitor of protein degradation that
blocks the fusion of the endosome with the lysosome [50] (Fig 3E). These data suggest that
caveolae containing TGFBIp is also targeted by lysosomes for degradation after internalization.
Expression of exogenous caveolin-1 induces the formation of caveolae on the surface of cells
that normally do not form them [51]. Furthermore, knockout of the gene encoding caveolin-1
in mice also reduces the expression of caveolin-2 and leads to the loss of morphologically de-
fined caveolae [52]. These studies suggest a possible correlation between the expression of
caveolins and the efficiency of TGFBIp endocytosis. Therefore, we examined the expression of
caveolin-1 and -2 in cells that have different internalization levels of TGFBIp (Fig 4A). Caveo-
lin-1 and -2 proteins showed cell-specific expression pattern (Fig 4A). Specifically, caveolin-1
was more abundant in SK-N-MC cells than in the NIH3T3 cells. Longer exposure of the blots
showed a very low level of caveolin-1 expression in ZW13-1 cells. Caveolin-2 also showed dif-
ferential expression with a moderate level of expression in ZW13-1 cells and a higher level in
the NIH3T3 and SK-N-MC cell lines (Fig 4A). However, HEK293T cells had no detectable ex-
pression of caveolin-1 and caveolin-2 (Fig 4A), consistent with previously published data [53].
However, the low-level expressions of CAV-1 were detected at mRNA level by RT-PCR (S1
Fig). Taken together, these results demonstrate that the expression of caveolin-1 protein closely
resembled that of caveolin-2 and that there was a clear correlation between the cellular expres-
sion levels of caveolins and the endocytosis of TGFBIp in these cell lines. These results also sug-
gest that the expression levels of caveolin-1 and -2 might influence TGFBIp endocytosis in
corneal fibroblasts. Therefore, we analyzed the expression levels of caveolin-1 and -2 in WT
Lysosomal Trafficking of TGFBIp
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Fig 3. Effect of inhibitors of caveolae- and clathrin-dependent endocytosis on TGFBIp internalization.
A. Inhibitors of endocytosis decreased TGFBIp levels in corneal fibroblasts. Cells were left untreated (lane 1) or
treated with Baf-A1 and various endocytosis inhibitors for 60min before incubation with TGFBIp for 120 min.
TGFBIp levels were determined by western blot analysis. GS; genistein, NS; nystatin, CM; chlorpromazine.
Data from one representative experiment is shown. β-actin was used as a loading control.B. Densitometric
quantitation of the experiment presented inA. Data represent the TGFBIp/β-actin ratio and expressed as
mean ± SD of three independently treated samples from one or two experiments. ANOVA analysis of TGFBIp
levels across the treatment conditions showed no significant changes. *P0.05 relative to controls by Student’s
t-test.C. Internalization of TGFBIp inWT corneal fibroblasts and caveolin-1-null cell line (3T3 MEF CAV-1 KO).
3T3 MEF CAV-1 KO cell does not express TGFBIp (lane 2 and 4). TGFBIp was internalized in corneal
fibroblasts (lane 5) but not in 3T3 MEFCAV-1 KO cell lines (lanes 6 and 8). Cells were pre-incubated at 37°C for
Lysosomal Trafficking of TGFBIp
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and GCD2 corneal fibroblasts. Fig 3B shows that corneal fibroblasts differentially express
caveolin-1 and -2, but the levels of expression did not differ significantly between WT and
GCD2 corneal fibroblasts (Fig 4B and 4C).
To confirm the presence of caveolae and caveolar vesicles (caveosomes) in corneal fibro-
blasts, we performed ultrastructural studies using transmission electron microscopy. Electron
micrographs of corneal fibroblasts showed flask-shaped invaginations of the cell membrane
and abundant membrane-associated vesicles (Fig 4D, panels 1 and 3). In this cell, caveolae also
appeared to undergo fusion to form caveosomes (Fig 4D, panels 2 and 4). These results con-
firmed the presence of caveolae and caveosomes in human corneal fibroblasts.
To determine whether TGFBIp resides in the caveolae in corneal fibroblasts, we analyzed
the distribution of these proteins on ultrathin cryosections. Sections of WT corneal fibroblasts
were labeled with anti-TGFBIp. TGFBIp-gold signal (arrow) were found in invaginated struc-
tures (caveolae) (arrow head in Fig 4E① and 4E②) on the plasma membrane. TGFBIp-gold
signal (arrow) also is distributed in the cytosol (arrow in Fig 4E②) and the lysosomes of WT
corneal fibroblasts (circle in Fig 4E③ and 4E④). Caveolae-like structures also appeared in the
lysosomes (arrow head in circle of Fig 4E④). Based on these data, we conclude that TGFBIp
may reside in the caveolae both at the plasma membrane and inside the cell.
Internalized TGFBIp is transported to lysosomes for degradation
To determine whether internalized TGFBIp is degraded within the lysosomes, we assessed
the level of TGFBIp and its co-localization with lysosomes in the NIH3T3 and ZW13-1 cells
treated with Baf-A1. We detected a significant increase in TGFBIp in both the cell types after
treatment with the inhibitor (Fig 5A and 5B), indicating that TGFBIp is degraded by lysosome-
mediated proteolysis or autophagy after internalization. Confocal microscopy revealed that in-
ternalized TGFBIp co-localized with the lysosomal marker Lamp-2, but not the ER marker
GRP94, in NIH3T3 cells (Fig 5C). Furthermore, increased co-localization of internalized
TGFBIp with caveolin-1 was observed in the cells treated with Baf-A1 (Fig 5D). These data pro-
vide additional supportive evidence that extracellular TGFBIp is internalized by cells and then
targeted to the lysosomes for degradation.
Interaction of an RGD-motif on TGFBIp with αvβ3 integrin mediates
TGFBIp entry into cells
Integrins are known to be constitutively endocytosed and recycled [54,55]. Previous studies
demonstrated that TGFBIp interacts directly with several integrins, including αVβ3, through
mechanisms dependent and independent of the RGD binding motif [56,57]. These data suggest
60min in basal medium or basal medium with CHX, and then incubated for a further 60min at 37°C in basal or
TGFBIp-supplemented (~1 μg/mL) medium with or without CHX. Cells were washed twice with cold PBS on ice,
and surface-bound TGFBIp was removed by washing three times with ice-cold acidic buffer. Cells were
harvested by scraping into ice-cold PBS, pelleted by centrifugation at 1,000 × g, lysed in RIPA buffer, and 50 μg
of total protein was used for western blot analysis.D. TGFBIp co-localizes with caveolin-1 in corneal fibroblasts.
Cells were grown on glass slides for 12 h and then fixed using methanol at −20°C and incubated with antibodies
against TGFBIp and caveolin-1. Localization of TGFBIp (green) and caveolin-1 (red) are shown. Areas of
TGFBIp and caveolin-1 co-localization appear as yellow regions in themerged image. The boxed area in the
third panel wasmagnified and is presented as the fourth panel. Arrows in the fourth panel identify regions of
TGFBIp and caveolin-1 co-localization.E. Cathepsin D co-localizes with caveolin-1 in corneal fibroblasts in the
absence and presence of Baf-A1. Cells were grown on glass slides for 12 h in the absence (upper panel) or
presence (lower panel) of Baf-A1 (0.1 μM) and then fixed with methanol at −20°C and incubated with antibodies
against cathepsin D and caveolin-1. Localization of cathepsin D (green) and caveolin-1 (red) is shown. Areas of
cathepsin D and caveolin-1 co-localization appear as yellow regions in the merged image.
doi:10.1371/journal.pone.0119561.g003
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that the RGDmotif mediates the internalization of TGFBIp through interaction with integrins.
Therefore, we evaluated whether RGD-mediated interactions of TGFBIp with integrins are in-
volved in its internalization. Exogenous human TGFBIp was incubated with corneal fibroblasts
in the presence of either RGD peptide or control RAD peptide for 2 h. In the presence of the
RGD peptide, the amount of internalized TGFBIp was reduced in a dose-dependent manner
Fig 4. Expression of caveolin-1 and -2 in established cell lines and caveolae formation in WT, HE, and HOmutant TGFBIp-expressing primary
cultured corneal fibroblasts. A. Total cellular protein (50 μg) from the specified cell lines was subjected to western blot analysis with anti-caveolin-1 (first
panel), anti-caveolin-1 (second panel, LE: longer exposure), anti-caveolin-2 (third panel), and anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH,
fourth panel). GAPDHwas used as a loading control.B. Western blot analysis of caveolin-1 and -2 expressions in WT, HE, and HO TGFBIp-expressing
corneal fibroblasts. β-actin was used as a loading control.C. Densitometric quantitation of the experiment presented in B. D. Transmission electron
microscopy (TEM) of corneal fibroblasts reveals formation of caveolae in corneal fibroblasts. Cells were grown in basal media, fixed, and then prepared for
scanning TEM as described in Materials and Methods.① Caveolae are detected on the inner surface of the plasmamembrane of corneal fibroblasts. Cells
contain caveolae in their apical membranes that are characterized by coat-free flask-shaped invaginations (asterisks in③) with a diaphragm at the neck
(arrows in③).②Note the characteristic clustering of caveolae into racemose structures, or caveosomes, on the basal side (④ asterisks). Bar = 500 nm. E.
At steady state, TGFBIp is localized in the caveolae both at the plasmamembrane and inside the cell. TGFBIp was immunogold-labeled on ultrathin
cryosections of WT corneal fibroblasts using the TGFBIp monoclonal antibody.① and② plasmamembrane caveolae-like structures (arrowhead) appeared
as flask-shaped invaginations on the plasmamembrane (p).③ and④ Ultrathin cryosections were labeled with anti-TGFBIp antibodies. TGFBIp-gold signal
(arrow) accumulated in the lysosomes of WT corneal fibroblasts.④Caveolae-like structures also appeared in the lysosomes (circle). The scale bars in all
panels are 100 nm.
doi:10.1371/journal.pone.0119561.g004
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(Fig 6A, left panel). However, intracellular TGFBIp levels did not change in cells incubated
with the control RAD peptide (Fig 6A, right panel). These results suggest that RGD peptides
disrupt TGFBIp internalization by preventing its endocytosis from the ECM.
Fig 5. Internalized TGFBIp is transported to lysosomes. A. NIH3T3 and ZW13-1 cells were pre-incubated
for 60 min in the absence (-) or presence (+) of Baf-A1. After incubation, cells were incubated for 120 min in
normal media containing TGFBIp and western blotting was performed for TGFBIp.B. Densitometric
quantitation of the experimental results presented inA. A Student’s t-test was performed to determine the
significance of differences between treatments with and without Baf-A1. Data analysis showed that the p-
value was less than 0.05, indicating statistical significance. The experiment was repeated three times
independently. C. Co-localization of TGFBIp with GRP94, ERmarker, and Lamp-2, lysosomemarker, in
NIH3T3 cells. Cells were subjected to immunocytochemical staining as described in Materials and Methods.
Areas of co-localization appear as yellow regions in the merged image. The boxed area in the third panel was
magnified and is presented as the fourth panel.D. Co-localization of TGFBIp with caveolin-1 in the absence
(upper panel) and presence (lower panel) of Baf-A1. NIH3T3 cells were grown on glass slides and treated
with vehicle or Baf-A1 (0.1 μM) for 60 min before incubation for 30 min at 4°C in medium containing ~1 μg/mL
TGFBIp. The cells were subjected to immunocytochemical staining as described in Materials and Methods.
The boxed area in the third panel was magnified and is presented as the fourth panel.
doi:10.1371/journal.pone.0119561.g005
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Fig 6. Integrin-dependent endocytosis of TGFBIp in corneal fibroblasts. A. Endocytosis of TGFBIp was
blocked by RGD peptide in a dose-dependent manner. Corneal fibroblasts were pre-incubated for 30 min in
the absence (lane 1) or presence (lanes 2–4) of RGD or RAD peptides. TGFBIp (~1 μg/mL) was added to the
medium and the cells were incubated for 120 min at 37°C. TGFBIp levels were measured by western blot
analysis. B. TGFBIp interacts with integrin αVβ3 and αV. Cells were lysed with RIPA buffer and the lysate was
immunoprecipitated with anti-integrin αVβ3 (left-hand panel) or anti-integrin αV (right-hand panel) antibody as
indicated. Immunoprecipitates were resolved on 10% SDS-PAGE gels and immunoblotted with anti-TGFBIp
polyclonal antibody.C. Co-localization of integrin αV with TGFBIp was visualized by confocal
immunofluorescence microscopy. The merged images show TGFBIp as red, integrin αV as green, and areas
of co-localization as yellow. The boxed area in the lower left-hand panel was magnified and is presented as
the lower right-hand panel. Arrows identify regions of TGFBIp and integrin αV co-localization. Scale bars,
5 μm. D. Western blot analysis of HEK293T, NIH3T3, SK-N-MC, and ZW13-1 cell lines with monoclonal
antibody against integrin αV. GAPDHwas used as a loading control.
doi:10.1371/journal.pone.0119561.g006
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We also examined the potential association of TGFBIp with αVβ3 integrin by co-immuno-
precipitation. Cell lysates from corneal fibroblasts were subjected to immunoprecipitation with
specific antibodies against integrin αV or αVβ3, and the resulting immunoprecipitates were ana-
lyzed for the presence of TGFBIp by western blot. Our data demonstrate that TGFBIp was co-
immunoprecipitated by both integrin αV and αVβ3 antibodies (Fig 6B), suggesting the associa-
tion between integrin αVβ3 and TGFBIp. Consistent with these results, confocal microscopy
analysis showed the co-localization of internalized TGFBIp and integrin αV in corneal fibro-
blasts (Fig 6C). Taken together, these data demonstrate that TGFBIp is internalized via the in-
teraction of αVβ3 or/and αVβ5 integrins with an RGD-motif in TGFBIp. The variations in
TGFBIp internalization among different cell lines (Fig 2A) may depend on the expression level
of integrins as cell surface receptors for TGFBIp. Therefore, we assayed the levels of integrin αV
expression in these cell lines. Although the expression of integrin αV showed a different pattern
between human (HEK293T and SK-N-MC) and mouse (NIH3T3 and ZW13-1) cell lines, the
protein was expressed at a similar level in all the four cell lines (Fig 6D).
Ubiquitin-mediated proteasome activity is required for internalization of
TGFBIp
Ubiquitination plays a role not only in proteasome-mediated protein degradation, but also in
receptor-mediated endocytosis. One of the non-proteasome functions of ubiquitination is its
implication in the process of endocytosis [58]. Therefore, we assessed whether ubiquitination
has any effect on TGFBIp endocytosis. To examine the endocytosis of TGFBIp in corneal fibro-
blasts, we measured TGFBIp internalization after treatment with cycloheximide (CHX), which
inhibits translation. As expected, CHX treatment inhibited the expression of TGFBIp (Fig 7A,
lane 2). The level of intracellular TGFBIp increased in corneal fibroblasts treated with exoge-
nous TGFBIp, unlike that in the non-treated cells (Fig 7A, lane 4 compared to lane 1). Further-
more, treatment with a chemical inhibitor of the 26S proteasome, MG132, dramatically
decreased the level of intracellular TGFBIp after treatment with exogenous TGFBIp (Fig 7A,
lane 4 compared to lane 7), suggesting that TGFBIp internalization is facilitated by the ubiqui-
tin-proteasome activity. The addition of MG132 to cells treated with Baf-A1 in the presence of
CHX further reduced the level of intracellular TGFBIp (Fig 7A, lane 8 compared to lane 5), in-
dicating that ubiquitination is necessary for TGFBIp intracellular trafficking to lysosomes.
To confirm whether changes in the levels of intracellular TGFBIp induced by MG132 and
Baf-A1 treatments was caused by internalized or newly synthesized TGFBIp, we measured
TGFBImRNA expression in cells treated with and without various concentrations of MG132
or/and Baf-A1 in the presence of CHX for 120 min by RT-PCR. These inhibitors did not
change TGFBImRNA levels (Fig 7B), indicating that MG132 or/and Baf-A1 treatments did not
regulate TGFBI gene levels, but affected the endocytosis pathway of TGFBIp.
Discussion
Despite the demonstration of the role of TGFBIp accumulation in the pathogenesis of TGFBI-
linked corneal dystrophy, the molecular mechanisms involved in extra- and intracellular traf-
ficking of TGFBIp are poorly understood. Cultured corneal fibroblasts from patients with
GCD2 exhibit the accumulation of TGFBIp in the lysosomal compartments, suggesting dys-
functional TGFBIp trafficking and turnover.
Current therapeutic strategies for the treatment of TGFBI-linked corneal dystrophy are fo-
cused on inhibiting TGFBIp expression by blocking the TGF-β signaling pathway [59]. Howev-
er, this strategy may affect other critical functions of TGFBIp, such as cell adhesion [60], cell
migration [60], and wound healing [10]. Therefore, long-term treatment could result in injury
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to the cornea in addition to side effects associated with disrupting the crosstalk between TGF-
β/Smad and other signaling pathways. Most importantly, blocking TGF-β signaling can result
in the dysregulation of cell growth. Therefore, degradation of mutant TGFBIp via internaliza-
tion before or/and after deposition in the ECM is a potentially effective strategy for targeted
drug intervention in TGFBI-linked corneal dystrophy.
In this study, we investigated the trafficking of WT and mutant TGFBIp. Our data demon-
strate that TGFBIp is secreted through an ER/Golgi-dependent pathway, and that this secretion
is delayed in GCD2 corneal fibroblasts. TGFBIp is internalized via a caveolin-dependent endo-
cytic pathway and transported to the lysosomes for degradation. This internalization is mediat-
ed by RGDmotif-dependent binding of TGFBIp to integrin αVβ3 or αVβ5. Finally, our results
demonstrate that the ubiquitin-proteasome system regulates TGFBIp endocytic trafficking.
TGFBIp was detected in our western blot analysis as two bands (~66 kDa and ~68 kDa).
Previous studies have suggested that these bands reflect the absence or presence of a signal pep-
tide, alternative splicing of the TGFBI gene [61], or proteolytic processing [62]. In this study,
neither band was affected by treatment with BFA nor MON, drugs that disrupt trafficking
Fig 7. Effects of proteasome inhibitors on TGFBIp internalization. A. Corneal fibroblasts were treated
with CHX (to inhibit translation), and MG132 (proteasome inhibitors) or Baf-A1 (lysosomal inhibitors) for
60 min at 37°C, and then incubated with or without TGFBIp for 120 min at 37°C as indicated. The TGFBIp
level was analyzed by western blotting.B. RT-PCR analysis of the effect of the specified inhibitors on the
mRNA levels of TGFBI.
doi:10.1371/journal.pone.0119561.g007
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from the ER to Golgi or from the Golgi to ECM, respectively. Additionally, both bands were de-
tected in samples of conditioned media, although only the ~ 68 kDa band was detected in cells
and conditioned media throughout the pulse/chase experiment. These results suggest that the
~66 kDa protein might have been generated by proteolytic cleavage by proteases in the ECM
prior to internalization via endocytosis.
Studies have demonstrated that abnormal regulation of ECM components contributes to
the progression of many diseases, including fibrosis and cancer [27–29,31]. Therefore, we pos-
tulate that the ~66 kDa form of TGFBIp might be important in the progression of TGFBI-
linked corneal dystrophy and might facilitate the physiological process related to ECM remod-
eling, wound healing, development, and cancer. Furthermore, several studies have shown that
proteolytic processing of mutant TGFBIp is involved in the pathogenesis of TGFBI-linked cor-
neal dystrophy [62–64]. Recent studies have shown the accumulation of different proteolytic
fragments of TGFBIp with diverse cleavage sites in the amyloid deposits of patients with
TGFBI-linked corneal dystrophy. Taken together, these results suggest that further proteolysis
of this ~66 kDa form by proteases such as matrix metalloproteinases could generate corneal-
specific deposition and/or amyloid via distinct aggregation pathways in corneal tissue. Further
investigation is required to examine these hypotheses.
Turnover of ECM proteins is an important mechanism for the removal of biologically active
proteins from the extracellular environment. Proteins can be degraded in the extracellular
space by proteases [23,24] or undergo intracellular degradation in lysosomes or by autophagy
after endocytosis [25,26,65,66]. Previous studies have established that the degradation and re-
moval of ECM proteins is involved in development, postnatal tissue remodeling, and tissue re-
pair [5,67]. Accordingly, abnormal degradation and removal of ECM components could
contribute to many diseases, including fibrosis, arthritis, and cancer [27–31]. We have previ-
ously demonstrated the accumulation of mutant TGFBIp in cytoplasmic or lysosomal com-
partments due to defective autophagy or delayed fusion between autophagosomes and
lysosomes in GCD2 corneal fibroblasts [33]. Therefore, delayed fusion between lysosomal
compartments and internalized caveolae and/or caveosome vesicles containing TGFBIp should
be the subject of future studies.
Our data using immune-electron microscopy, confocal microscopy, and pharmacological
inhibitors demonstrate that TGFBIp may be internalized via caveolae-mediated endocytic
pathways. Furthermore, Cav-1–null cells failed to show internalization of TGFBIp. Caveolae
and caveosome vesicles are abundant in corneal fibroblasts, indicating an active caveolae-medi-
ated endocytosis in these cells. It is interesting to speculate on the possibility that the internali-
zation of mutant TGFBIp could be inhibited in GCD2 corneal fibroblasts by mechanisms
involving the polymerization of mutant TGFBIp and age-related failure of endocytosis [68].
Levels of caveolin protein are upregulated in an age-dependent manner in senescent fibroblasts
and aged animal tissues [69,70]. This might explain the age-dependent accumulation of mutant
TGFBIp in corneal stroma. However, in our study, the expression levels of caveolin-1 and -2
did not differ significantly between WT and GCD2 cells. These findings point to an important
therapeutic application for TGFBI-linked corneal dystrophy, because mutant TGFBIp could be
removed by endocytosis by corneal fibroblasts in the corneal stroma. Our data demonstrate
that TGFBIp co-localized with integrins in the intracellular vesicles in corneal fibroblasts.
Moreover, we showed that TGFBIp interacted with αV integrin, and that RGD peptide inhib-
ited TGFBIp internalization in a dose-dependent manner. These data suggest that the RGD
motif could mediate interaction with integrins, even though TGFBIp is also able to interact
with integrins in the absence of this motif [71]. Although the internalization of most integrins
occurs via a clathrin-mediated process [72,73], caveolin-1 has been shown to regulate the endo-
cytosis of fibronectin-binding β1 integrins [74]. Our data indicate that TGFBIp internalization
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may depend on the expression of integrin or/and caveolins. However, HEK293T cell did not
internalize TGFBIp even they do express avb3 integrin. “It has been demonstrated that integ-
rins, α5β1, α8β1, αIIbβ3, αVβ1, αVβ3, αVβ5, αVβ6, and αVβ8, can recognize RGD motifs in
their ligands [75]. These data reveal that TGFBIp could interact with these integrins, and may
be internalized via caveolae or/and clathrin-mediated endocytosis or/and other pathways. The
internalization of many integrin heterodimers occurs by clathrin‑dependent, clathrin‑indepen-
dent, and caveolin‑dependent endocytic mechanisms. Integrin heterodimers can follow more
than one internalization route. For example, α5β1 integrin can be internalized by both cla-
thrin‑dependent [76] and caveolin‑dependent endocytic mechanisms [74]; αvβ3 integrin is re-
cruited to caveolae and internalized in caveolin 1-dependent manner [77] and can also enter
the cell via clathrin‑coated pit structures [78]. Furthermore, recent advances in understanding
of integrin endocytosis have elucidated the molecular connection between the integrin and
endocytic machineries, such as adaptors and associated proteins [79]. In addition, pathways of
integrin internalization are cell type-dependent and rely on cellular processes, such as migra-
tion etc. [79]. Moreover, several integrins, αvβ3 [77], α5β1 [74], and αLβ2 [80], are internalized
via caveolin‑dependent endocytosis [77]. Given these data, although we cannot rule out that
TGFBIp is also internalized via clathrin‑dependent and other endocytic mechanisms, at the
very least our data indicate that integrin αVβ3 may mediate the internalization of TGFBIp via
a caveolin-dependent pathway. Further, this data indicate that TGFBIp endocytosis might be
depending on the expression of caveolin-1 and -2 rather than the expressions of integrin avb3
or other integrins. This possibility is further supported by the differences in the rate of TGFBIp
internalization among HEK293T, NIH3T3, SK-N-MC, and ZW13-1 cell lines. We showed that
caveolin-1 and -2 were expressed differentially in NIH3T3, SK-N-MC, and ZW13-1 cell lines,
but were not expressed in the HEK293T cell line. Additionally, HEK293T cells express higher
levels of αV, α5, and β1 integrin, but the expression of αVβ3 and αVβ5 integrin is undetectable
[81,82]. These data suggest that HEK293T cells do not possess caveolae-dependent endocytic
pathways for TGFBIp, which in turn might have contributed to the inability to detect TGFBIp
internalization in these cells. However, we cannot rule out a very low rate of TGFBIp internali-
zation in HEK293T cells. Taken together, our findings indicate that the expression of caveolins
and αVβ3 integrin may play a significant role in the degradation of TGFBIp via endocytosis.
This notion is supported by previous evidence that TGFBIp function is directly linked to integ-
rin signaling [13].
The ubiquitin-proteasome system regulates receptor-mediated endocytosis through the ubi-
quitination of the internalized receptor [83,84]. The reduction in TGFBIp levels after MG-132
treatment indicates that TGFBIp internalization is regulated by ubiquitin-proteasome activity.
Accordingly, the reduced level of TGFBIp in the presence of MG132 may be due to the inhibi-
tion of endocytosis rather than increased degradation. We postulate that the reduced activity of
the ubiquitin-proteasome system could induce the accumulation of mutant TGFBIp in the
ECM by inhibiting internalization. Age-dependent TGFBIp accumulation and deposition has
been observed in the corneal stroma of patients with TGFBI-linked corneal dystrophy. The
ubiquitin-proteasome system exhibits a gradual decrease with age [85] in a variety of tissues,
including the eye [85–89]. Furthermore, we have previously shown that the levels of polyubi-
quitinated proteins are higher in GCD2 corneal fibroblasts than in the WT cells, indicating
the loss of proteasome activity in GCD2 corneal fibroblasts [33]. Taken together, these results
support the hypothesis that impaired TGFBIp endocytosis resulting from an age-dependent
decrease in the ubiquitin-proteasome system leads to age-dependent accumulation and deposi-
tion of TGFBIp in TGFBI-linked corneal dystrophy. However, further studies are required to
understand the mechanism by which accumulation and aggregation of mutant TGFBIp is asso-
ciated with the ubiquitin-proteasome system.
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Conclusion
Our data suggest that a disturbance in the intracellular trafficking of mutant TGFBIp can lead
to TGFBIp-linked corneal dystrophies. Furthermore, it seems reasonable to hypothesize that
altered ECM turnover, which is regulated by endocytosis, can trigger the aggregation, deposi-
tion, and accumulation of mutant TGFBIp in the corneal stroma. A better understanding of
the molecular events involved in the intracellular and extracellular trafficking of ECM proteins
such as TGFBIp will allow us to better address this phenomenon. Such knowledge might lead
to the identification of novel targets and the development of new therapies for the treatment of
TGFBI-linked corneal dystrophy.
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